In a cross-sectional study, we evaluated the impact of the chronic use of benzodiazepines (BDZ) prescribed for seizure control on the anxiety levels of patients with temporal lobe epilepsy. We assessed the anxiety level of 99 patients with temporal lobe epilepsy with (n = 15) or without (n = 84) BDZ for seizure control, using the Beck Anxiety Inventory (BAI) or the Hamilton Anxiety Scale (HAMA). Independent risk factors for high anxiety levels were being a female patient (O.R. = 2.93; 95% C.I. = 1.05-8.16; p = 0.039), having uncontrolled seizures (O.R. = 4.49; 95% C.I. = 1.66-12.11; p = 0.003) and having a history of a psychiatric disorder (O.R. = 4.46; 95% C.I. = 1.63-12.21; p = 0.004). However, there were no statistically significant differences in anxiety levels between patients utilizing or not utilizing BDZ prescribed exclusively for seizure control. We concluded that in our study, patients with chronic use of BDZ prescribed exclusively for seizure control showed similar anxiety levels than patients who were not using this class of drug. Additional studies are needed to define better strategies for the treatment of anxiety disorders in epilepsy.
Introduction
Epilepsy is a frequent disease, occurring in 0.5 to 1.5% of the population [1] . The association between epilepsy and psychiatric disorders is well recognized and has been extensively studied. Psychiatric comorbidities occur in 20-80% of patients with epilepsy [2, 3] . This broad range prevalence might be due to the different populations studied and to the variability of the diagnostic criteria used. In a community-based study, Tellez-Zenteno et al. used the Canadian Community Health Survey-Mental Health and Well-Being (CCHS-MHWB) to analyze the prevalence of psychiatric comorbidities in epilepsy [4] . These authors reported that individuals with epilepsy were more likely than individuals without epilepsy to report lifetime anxiety disorders or suicidal thoughts [4] . In our patients with temporal lobe epilepsy (TLE), we observed high levels of psychiatric comorbidities, and our results are comparable to those reported for European populations [5, 6] . Some data suggest that genetic and anatomically common neural networks might merge together leading to the development of psychiatric comorbidities in epilepsy [7] [8] [9] [10] .
There is much evidence that the presence of psychiatric disorders in patients with epilepsy has a stronger impact on quality of life than other clinical variables, including frequency or severity of seizures [11, 12] . For example, depression but not seizure control might predict quality of life in epilepsy [12] . Although anxiety comorbidities are as frequent as mood disorders in epilepsy, risk factors for their development or their impact on patients are much less studied, and their treatment still needs to be better defined [13] .
Benzodiazepines (BDZ) are frequently used as an add-on therapy for seizure control in epilepsy [14] [15] [16] . These drugs can also be used for the treatment of anxiety disorders [17] [18] [19] . It might be intuitive to some neurologists to consider that BDZ could be used to control seizures and reduce anxiety levels associated with epilepsy in some patients. Thus, we designed this study to evaluate the impact of BDZ chronically used as an add-on therapy for seizure control on anxiety levels in patients with epilepsy. Our study might be relevant for the treatment of anxiety disorders in patients with epilepsy.
Methods

Subjects
This was a cross-sectional study conducted on 99 consecutive patients (62 women and 37 men) with TLE. [20] .
The inclusion criterion for the study was the presence of electroclinical and neuroimaging features of TLE, according to the ILAE classification for epileptic seizures and syndromes. Patients less than 18 years of age, those with generalized epilepsies, extratemporal epilepsies, mental retardation (IQ scores below 70), brain tumor, systemic disease, or penetrating head trauma, and those patients in treatment for depression or anxiety were excluded. Only patients using BDZ strictly as an adjuvant drug for seizure control (e.g. clobazam or clonazepam) were included in the study. Patients using BDZ for a reason other than seizure control were also excluded from the study. After giving written informed consent, all patients were submitted to the Beck Anxiety Inventory (BAI) and Hamilton Anxiety Scale. The BAI scale classifies patients into four levels: minimum, mild, moderate, and severe anxiety levels. In order to facilitate data analysis and presentation, the results of the BAI scale were divided into two major groups, i.e., patients with low anxiety levels (minimum or mild anxiety levels) and patients with high anxiety levels (moderate or severe anxiety levels). The two different scales were used in order to obtain more accurate results. All patients were previously evaluated with the Structured Clinical Interview for DSM-IV (SCID), for the detection of one or more lifetime diagnoses of the Axis I Diagnostic and Statistical Manual, fourth edition (DSM-IV). Clinical charts were reviewed for EEG and neuroimaging findings. Control of seizures was assessed with an event calendar filled out by the patient and revised during visits. Seizures occurring more than once a year were considered to be uncontrolled. Data regarding current antiepileptic treatments, including BDZ used strictly as adjuvant drugs for seizure control, were recorded in a database for later analysis. The study was approved by the Ethics Committee of our institution and conformed to the ethical standards as defined by the Declaration of Helsinki. All persons included in the study gave written informed consent prior to their inclusion in the study.
Statistical analysis
The clinical and electroencephalographic variables and anxiety levels were compared between TLE patients taking or not taking BDZ for seizure control. Categorical variables were compared using Fisher's exact test. Numerical variables were compared using the independent Student t-test with the Levene test for equality of analysis of variance. All statistical analyses were carried out using the SPSS 16.0 statistical package for Windows (SPSS Inc., Chicago, IL, USA). Results are expressed as mean (standard deviation) or percentages (odds ratio; 95% confidence interval). We used a logistic regression model in order to further examine the independent effect of each risk factor in contributing to high anxiety levels in patients with epilepsy and to control for confounding factors regarding the use or not of BDZ. The level of significance was set at p b 0.05.
Results
Variables according to the use of BDZ are listed in Table 1 . The mean age of the patients was 45.63 (±13.18) years, mean age of epilepsy onset was 20.98 (±14.58) years, and mean time of epilepsy was 24.25 (±14.76) years. In our sample, patients taking BDZ had a lower mean age of epilepsy onset. Fifteen patients (15.15%) were using BDZ strictly prescribed as adjuvant drugs for seizure control. Of these, 13 (86%) were using clobazam (a mean dose of 24 mg/day, ranging from 10 to 40 mg/day) and 2 (14%) were using clonazepam (a mean dose of 2 mg/day, ranging from 2 to 2 mg/day). As expected, the use of BDZ was more common among patients with refractory epilepsy (O.R. = 5.6; 95% CI = 1.97-11.06; p = 0.047) since BDZ were used in an attempt to control seizures in these patients. No other difference was observed between the two groups of patients. Table 2 shows the variables according to anxiety levels. In order to facilitate evaluation, anxiety levels are expressed as BAI low anxiety (minimal or mild anxiety levels) or BAI high anxiety (moderate or severe anxiety levels). Hamilton results (Total Hamilton Score, Hamilton Psychic Subscale, and Hamilton Somatic Subscale) are reported as mean (±S.D.). Overall, we observed that being a woman or having anxiety or mood disorders as detected previously by SCID was associated with higher anxiety in BAI or Hamilton Total scores. BAI detected high levels of anxiety also in patients with uncontrolled seizures, and Hamilton scores showed higher anxiety levels in patients with a family history of psychiatric disorders. No other differences were observed (Table 2) . Moreover, there were no differences when mean age of patients or mean age of seizure onset was compared between groups of BAI low anxiety and BAI high anxiety levels. Also, there was no correlation between mean age of patients and mean age of seizure onset regarding the results of the Hamilton Anxiety Scale (data not shown). Table 3 shows the Hamilton Scale and the BAI results for patients using BDZ as an adjuvant drug for seizure control. An analysis of subgroups of patients with or without psychiatric disorders as detected by SCID showed similar findings (data not shown). Table 4 shows independent predictors of high anxiety in our patients. We forced into the model the use of BDZ in order to control its effects but again, failed to observe a positive effect of the chronic use of BDZ in decreasing anxiety levels in patients with TLE. Thus, in our study, patients with chronic use of BDZ prescribed exclusively for seizure control showed similar anxiety levels than those patients with epilepsy who were not using BDZ.
Discussion
Our results showed equivalent levels of anxiety among patients with epilepsy who were and who were not using benzodiazepines for seizure control. This was observed in the group of patients as a whole and also in those patients with or without psychiatric comorbidities previously detected by SCID. Thus, in spite of some biological plausibility and some expectations, our findings suggest that the chronic use of BDZ prescribed as an add-on therapy for seizure control might not be clinically effective for the treatment of anxiety symptoms in epilepsy.
The studies of anxiety disorders in epilepsy have been neglected, and treatments for this comorbidity in patients with epilepsy remain poorly explored [8, 13] . Moreover, because there is a well-known association between mood and anxiety disorders, most studies and clinical observations might not be sufficiently discriminatory to evaluate the real impact of these treatments on anxiety symptoms in epilepsy. When specific treatments for anxiety comorbidities in epilepsy are proposed, they are mostly based on psychiatric experience [8, 9] . In psychiatric patients, pharmacological treatments for anxiety disorders are based mainly on selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs) or BDZ. Besides being first line in anxiety disorder therapy, the use of SSRIs and TCAs is also effective for mood disorders, a comorbidity that is often associated with anxiety disorders in epilepsy. BDZ are not considered first line for the treatment of anxiety disorders due to tolerance or addiction. On the other hand, BDZ (e.g. clobazam and clonazepam) might be used as a chronic add-on therapy for seizure control [14, 18] . Thus, at least for some patients, BDZ would be perhaps natural candidates for the treatment of anxiety symptoms as well. However, in spite of some clinical and biological plausibility, our results do not support this idea. In fact, we observed that the anxiety levels were similar when patients with epilepsy chronically using BDZ as an add-on therapy for seizure control were compared to the respective control group.
In our study, independent variables associated with anxiety disorders in TLE were being a female or having anxiety or mood disorders as detected previously by SCID. These patients had higher anxiety scores when tested with BAI as well as with Hamilton. BAI also detected high levels of anxiety in patients with uncontrolled seizures, and Hamilton showed higher anxiety levels in patients with a family history of psychiatric disorders. The neurobiology of anxiety comorbidities in epilepsy remains not fully understood. Some authors relate anxiety as a reaction to real or imaginary threats, a view in line with learning and cognitivebehavioral theories, suggesting that anxiety is a conditioned response to stressful stimuli [8, 21, 22] . In this regard, it was interesting that in our study, we observed high levels of anxiety in patients with uncontrolled seizures. It is plausible that anxiety in epilepsy is provoked or at least potentiated by fear of seizures, a view in line with the learning and cognitive-behavioral theories. Nevertheless, this finding is also in line with other neurobiological hypotheses [8] . It is possible that insufficiency of neural substrates in regulating overexcitability and other mechanisms that render patients prone to refractory seizures also predispose patients to anxiety disorders. We also observed that female sex or having mood disorders was independently associated with higher anxiety levels in patients with epilepsy. Other authors have reported similar findings [23, 24] . Finally, it was interesting to observe that patients with a family history of psychiatric disorders (e.g. mood or anxiety disorders) showed higher anxiety levels on the Hamilton Rating Scale. This observation might suggest that genetic and molecular mechanisms might be involved in anxiety comorbidity in patients with epilepsy. Anxiety disorders in epilepsy are probably of multifactorial etiology, and it is possible that several factors merge together leading to the neuropsychiatric symptoms. Some of these factors were pointed out by our study.
We recognize that our study has limitations. It is a cross-sectional study and not a prospective study specifically designed for the evaluation of the impact and variability of effect of BDZ over time. Moreover, our study was not designed to evaluate the short-term effect of BDZ on anxiety symptoms. Although all patients underwent formal psychiatric evaluation with SCIDs, we did not analyze the impact of BDZ on specific sub-types of anxiety comorbidities in our patients. Also, in order to detect small effects of BDZ, the number of patients included in our study should have been higher. Moreover, since we did not obtain a pre-benzodiazepine anxiety baseline in our patients, we did not study the real effect of the BDZ prescription on the anxiety levels of these patients. Although we have carefully selected patients receiving BDZ exclusively prescribed for seizure control, we cannot completely exclude that more anxious patients were prescribed BDZ more often. Finally, the doses of BDZ were not very high, but were the maximum tolerated dosages for chronic use in these patients. However, on the other hand, our study has some merits that deserve recognition as well. We evaluated patients chronically taking BDZ with maximum tolerated doses. We used two different scales to evaluate anxiety symptoms, and we controlled the results for confounding variables, with congruent results for both scales. Studies evaluating the impact of the long-term use of BDZ on anxiety symptoms in pilepsy are clearly needed, and as far as we know, this is one of the first studies addressing the chronic effects of BDZ on the anxiety levels of patients with epilepsy. Thus, we believe that our results might help develop better treatment strategies for anxiety comorbidities in epilepsy in the near future.
Conclusion
In conclusion, we did not observe a difference in anxiety levels between patients using or not using BDZ chronically for seizure control. It is plausible that chronic use of BDZ could induce tolerance to the anxiolytic effect of these drugs in patients with epilepsy. In our view, additional studies are needed to define specific strategies for the treatment of anxiety disorders in epilepsy. Nevertheless, we hope that our study might help neurologists and psychiatrists in the decision-making process regarding the treatment of anxiety disorders in epilepsy in the near future.
